Nima Farzan, Kinnate CEO
May 13, 2021 04:03 PM EDTUpdated 05:00 PM
Financing
China

Ki­nase in­hibitor spe­cial­ist Kin­nate launch­es Shang­hai sub­sidiary with $35M to mar­ket its pro­grams in Chi­na

Max Gelman

Senior Editor

A lit­tle more than five months af­ter go­ing pub­lic with a $276 mil­lion IPO, Kin­nate Bio­phar­ma is back rais­ing mon­ey — this time for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times